|drug3199||Standard of care Wiki||0.19|
There is one clinical trial.
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
Description: Subject clinical status using the 7-point Ordinal Scale, specified as the primary endpoint in the WHO Master Protocol on day 15 as compared to baseline (1 - Not hospitalized, no limitations on activities; 2 - Not hospitalized, limitation on activities; 3 - Hospitalized, not requiring supplemental oxygen; 4 - Hospitalized, requiring supplemental oxygen; 5 - Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6 - Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 7 - Death).Measure: Clinical Status of the Patient (According to 7-point Ordinal Scale) Time: Day 1 (Baseline), Day 15
Description: Ordinal scale (OS) score status, time to improvement by 1 point for each OS score. Subject clinical status using the 7-point Ordinal Scale: - Not hospitalized, no limitations on activities; - Not hospitalized, limitation on activities; - Hospitalized, not requiring supplemental oxygen; - Hospitalized, requiring supplemental oxygen; - Hospitalized, on non-invasive ventilation or high flow oxygen devices; - Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; - Death.Measure: Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score Time: Days 1 - 29.
Description: NEWS scale score status, time to a discharge from a hospital or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first. NEWS score is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, temperature. A score of 0, 1, 2, 3 is allocated to each parameter except supplemental oxygen (a score 0 or 1 is allocated) and level of consciousness (a score 0 or 3 is allocated). A higher score means the parameter is further from the normal range. All scores were summed to get an aggregate score. Aggregate score ranges from 0 to 19, with higher scores meaning higher risk. Low risk - aggregate score, 1-4 Low to medium risk - score 3 in any single parameter, Medium risk - aggregate score 5-6, High risk - aggregate score 7-19.Measure: Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale)) Time: Days 1 - 29.
Description: Number of patients requiring supplementary oxygen on Days 3, 5, 8, 11, 15, 29Measure: Number of Patients Requiring Supplementary Oxygen Time: Days intervals 1 (baseline), 3, 5, 8, 11, 15, 29.
Description: Duration of hospitalisationMeasure: Hospitalisation Duration Time: Days 1 - 29
Description: Number of participants who were dead or alive (Days 1 - 29)Measure: Mortality Time: Days 1 - 29.
Description: The number of participants with serious adverse events (SAE)Measure: The Number of Participants With Serious Adverse Events Time: Days 1 - 29.
Description: The number of participants with adverse events (AE)Measure: The Number of Participants With Adverse Events Time: Days 1 - 29.
Description: Number of participants with Permanent or temporary discontinuation of infusions or injections due to adverse eventsMeasure: Number of Participants With Discontinuation of Drug Administration Time: Days 1 - 17.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports